Article Figures & Data
Figures
- FIGURE 1.
State of nuclear medicine in China. (A) Growth in number of departments and staff in nuclear medicine. (B) Number of SPECT/CT scanners and PET/CT scanners. (C–F) Applications of PET/CT (C), PET/MRI (D), SPECT/CT (E), and radionuclide therapy (F) in 2020. 99Tc-MDP = 99mTc-methylene diphosphonate.
- FIGURE 2.
Commercial radiopharmaceuticals under development. (A) Radiopharmaceuticals in different stages of clinic trial. (B) Indications for radiopharmaceuticals under investigation.
- FIGURE 3.
Metastatic castration-resistant prostate cancer patients with whole-body metastases treated with 177Lu-EB-PSMA at 1.85 GBq for each cycle, as shown with PSMA PET. (A–C) Patients treated with 1–3 cycles of 177Lu-EB-PSMA. After treatment, total-lesion PSMA (TLP), PSMA volume (PSMA-VOL), and prostate-specific antigen (PSA) were significantly decreased.
- FIGURE 4.
66-y-old patient with prostate cancer and bone metastases who received 4 cycles of therapy with 370 MBq of 177Lu-DOTA-ibandronate. (A) 68Ga-DOTA-ibandronate PET/CT image before treatment. (B–E) 68Ga-DOTA-ibandronate PET/CT images after each cycle. After 4 cycles of treatment, uptake of 68Ga-DOTA-ibandronate was significantly decreased. Arrows refer to metastases at L4-5 vertebra, and arrowheads refer to metastases at 10th rib on right side.
Tables
- TABLE 1.
Radiopharmaceuticals Under Commercial Clinical Development or in Market Approval Process in China
Drug Company Phase Indication NRT6003 injection Chengdu New Radiomedicine Technology Co., Ltd. I Therapy for primary and metastatic liver cancer 18F-fusiruitai injection Shanghai Lannacheng Biotechnology Co., Ltd. I Diagnosis of PSMA-positive lesions in prostate cancer patients 18F-fuxianyisu injection Yantai Lannacheng Biotechnology Co., Ltd. I Diagnosis of FAP-positive lesions in solid tumor patients 18F-florbetazine injection HTA Co., Ltd. I Diagnosis of Alzheimer disease related to β-amyloid neuritic plaques 18F-florastamin injection HTA Co., Ltd. I Diagnosis of PSMA-positive lesions in prostate cancer patients 18F-BF3-BPA injection Suzhou Boruichuanghe Biotechnology Co., Ltd. I Diagnosis of brain tumor lesions 68Ga-HX01 injection Suzhou Hexin Pharmaceutical Technology Co., Ltd. I Diagnosis of tumors that express αvβ3 or CD13 receptors 68Ga-natan recombinant PD-L1 single-domain antibody injection Suzhou Smartnuclide Biopharmaceutical Co. I PET imaging for assessment of PD-L1 expression levels in primary or metastatic lesions of solid tumor patients Kit for preparation of HRS-9815 Tianjin Hengrui Pharmaceuticals Co., Ltd. I Diagnosis of PSMA-positive lesions in prostate cancer patients HRS-9815 injection Tianjin Hengrui Pharmaceuticals Co., Ltd. I 99mTc-CNDG injection Beijing Shihong Drug Development Center I Diagnosis of benign and malignant tumors 131I-IPA injection Telix International Pty Ltd.; Grand Pharmaceutical Co., Ltd., China I Therapy for glioblastoma 131I-actuximab injection Shanghai Haikang Chinese Medicine Technology Development Co., Ltd. I Therapy for advanced malignant solid tumor 177Lu-JH020002 injection Bivision Biomedical Technology Co., Ltd. I Therapy for mCRPC HRS-4357 injection Tianjin Hengrui Pharmaceuticals Co., Ltd. I Therapy for mCRPC 177Lu-XT033 Sinotau Pharmaceuticals Co., Ltd. I Therapy for mCRPC 177Lu-vipivotide tetraxetan injection Advanced Accelerator Applications USA, Inc., Novartis Co. II Therapy for mCRPC NRT6008 injection Chengdu New Radiomedicine Technology Co., Ltd.; Chongqing HuaPont Pharmaceutical I Therapy for pancreatic cancer 18F-flutemetamol injection General Electric Pharmaceutical Co., Ltd., Shanghai I and II Diagnosis of Alzheimer disease related to β-amyloid neuritic plaques 18F-florbetapir injection Nanjing Jiangyuan AMS Positron Research and Development Co., Ltd. II Diagnosis of Alzheimer disease related to β-amyloid neuritic plaques 90Y-resin microspheres Grandpharma Co., Ltd., China II Therapy for inoperable primary liver cancer 188Re-HEDP injection Yantai Dongcheng Pharmaceutical Group Co., Ltd. II Palliation of bone pain caused by bone metastases BF3-BPA = boron trifluoride boronophenylalanine; CNDG = isonitrile deoxyglucosamine; IPA = 4-L-iodophenylalanine; mCRPC = metastatic castration-resistant prostate cancer; HEDP = hydroxyethylidene diphosphonate.
- TABLE 2.
Radiopharmaceuticals in Phase III of Commercial Clinical Development or Market Approval Process in China
Drug Company Indication 18F-alfatide injection Jiangsu Shimeikang Pharmaceutical Co., Ltd. Tumor diagnosis 18F-APN-1607 injection Suzhou Xinxu Pharmaceutical Co., Ltd. Diagnosis and evaluation of neurodegenerative diseases, including Alzheimer disease and cognitive impairment related to tau protein pathology 18F-florbetaben injection Tianjin HTA Isotope Medicine Co., Ltd. Diagnosis of Alzheimer disease related to β-amyloid neuritic plaques 18F-sodium fluoride injection Nanjing Jiangyuan AMS Positron Research and Development Co., Ltd.; HTA Co., Ltd. Diagnosis of bone metastasis of malignant tumor 6-18F-fluoro-l-dopa injection Jiangsu Huayi Technology Co., Ltd.; HTA Co., Ltd. Imaging to visualize dopaminergic nerve terminals in striatum for evaluation of suspected Parkinson disease in adult patients 18F-flortaucipir injection Beijing Xinhe Pharmaceutical Technology Co., Ltd. Diagnosis and evaluation of neurodegenerative diseases, including Alzheimer disease and cognitive impairment related to tau protein pathology Kit for preparation of 68Ga-PSMA-11 Novartis Pharma AG/Advanced Accelerator Applications USA, Inc., Novartis Co. Diagnosis of PSMA-positive lesions in prostate cancer patients 68Ga-PSMA-11 injection Telix Pharmaceuticals Inc., US Kit for preparation of 68Ga-DOTATATE HTA Co., Ltd. Diagnosis of somatostatin receptor–positive NETs in adults and children 68Ga-DOTATATE injection HTA Co., Ltd. Kit for preparation of 68Ga-edotreotide Tianjin Hengrui Pharmaceuticals Co., Ltd. Diagnosis of somatostatin receptor–positive NETs in adults and children 68Ga-edotreotide injection Tianjin Hengrui Pharmaceuticals Co., Ltd. 99mTc-3PRGD2 injection Foshan Ruidiao Pharmaceutical Co., Ltd. Diagnosis of benign and malignant lung tumors and lung lymph node metastasis 99mTc-GSA injection Beijing Shihong Drug Development Center Diagnosis of function and morphology of liver 99mTc-technetiumsulfur colloid injection HTA Co., Ltd. Diagnosis of primary tumor drainage area lymph nodes in adult breast cancer patients 123I-ioflupane injection GE Pharmaceutical Co., Ltd., Shanghai Diagnosis of Parkinson disease 90Y-glass microspheres Fangen Pharmaceutical Development Co., Ltd., Tianjin Therapy for unresectable primary liver cancer 131I-MIBG injection HTA Co., Ltd. Diagnosis of neuroblastoma and pheochromocytoma 177Lu-DOTATATE injection Advanced Accelerator Applications S.A.; Jingding Pharmaceutical Research and Development Co., Ltd., Shanghai Therapy for neuroendocrine tumor 177Lu-DOTATATE injection HTA Co., Ltd. Therapy for neuroendocrine tumor 177Lu-DOTATATE injection Sinotau Pharmaceuticals Co., Ltd. Therapy for neuroendocrine tumor 177Lu-DOTATATE injection Tianjin Hengrui Pharmaceuticals Co., Ltd. Therapy for neuroendocrine tumor 177Lu-DOTATOC injection ITM Solucin GmbH Therapy for neuroendocrine tumor APN = florzolotau; NETs = neuroendocrine tumors; GSA = galactosyl-human serum albumin; MIBG = metaiodobenzylguanidine.
In this issue
Jump to section
- Article
- Visual Abstract
- Abstract
- MILESTONES OF NUCLEAR MEDICINE IN CHINA
- STATUS OF CURRENT NUCLEAR MEDICINE
- PRODUCTION OF MEDICAL RADIOISOTOPES
- COMMERCIAL RADIOPHARMACEUTICALS
- DOMESTIC ADVANCED EQUIPMENT
- RESEARCH AND FUNDING OF NUCLEAR MEDICINE
- POTENTIAL OF NUCLEAR MEDICINE IN CHINA
- PROGRESS IN THERANOSTICS IN CHINA
- 68GA/177LU THERANOSTICS FOR NEUROENDOCRINE TUMOR
- 68GA/177LU THERANOSTICS FOR PROSTATE CANCER
- 68GA/177LU THERANOSTICS BY TARGETING FAP
- THERANOSTICS FOR BONE METASTASIS
- OTHERS
- PROCEDURES AND CHALLENGES OF THERANOSTICS
- THE FUTURE
- DISCLOSURE
- ACKNOWLEDGMENTS
- REFERENCES
- Figures & Data
- Info & Metrics